The translation of the heading to English is: "Medicaid Challenges Demand Elevance Health, but Strategic Course Remains Set.

Elevance Health continues to show resilience and reported a solid third quarter for 2024 with operating revenues of $44.7 billion – an increase of 5.3% compared to the previous year. Despite challenges in the Medicaid segment, the company managed to control costs, achieving an adjusted operating profit of $2.4 billion. However, losses in Medicaid membership led to a 19.8% decline in operating profit to $1.4 billion. These results reflect both the complexity of the current healthcare landscape and Elevance's adaptability through targeted cost reduction strategies. In the Health Benefits sector, there was a slight revenue increase of 4.2% to $38.3 billion; however, operating profit dropped by 12.5% to $1.6 billion due to the impact of Medicaid revaluations. These revaluations reduced membership numbers and affected margins. On the other side, Carelon, which includes pharmacy and care services, thrived with a revenue jump of 15% to $13.8 billion and an operating profit increase of 20% to $0.8 billion, driven by strong demand for its products and the integration of Paragon Healthcare. Looking ahead, Elevance is optimistic and announced a dividend of $1.63 per share for the fourth quarter of 2024 along with a stock buyback worth $60 million. The company expects a full-year GAAP net income of $26.50 per share and an adjusted net income of $33.00 per share. Despite ongoing Medicaid challenges, Elevance aims to achieve efficiency gains and emerge stronger from the situation, underscoring that the company is acting with a long-term focus.